Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $81.17 USD
Change Today +0.365 / 0.45%
Volume 353.0K
ICLR On Other Exchanges
As of 1:31 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

icon plc (ICLR) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/3/15 - $82.11
52 Week Low
08/29/14 - $49.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ICON PLC (ICLR)

icon plc (ICLR) Related Businessweek News

No Related Businessweek News Found

icon plc (ICLR) Details

ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It develops, manages, and analyzes programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company also offers clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics, and laboratory services. Its clinical development services include investigator recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety monitoring, risk-based monitoring, clinical data management, interactive response technologies, electronic patient reported outcomes, medical reporting, patient registries, outcomes research, health economics, market access and commercialization services, strategic analysis and data operations, bioanalysis, immunoassay development, pharmacokinetic and pharmacodynamic analysis, and study protocol preparation. The company’s clinical development services also comprise regulatory consulting, product development planning, strategic consulting, pricing and market access consulting, strategic resourcing, electronic endpoint adjudication, sample analyses, safety testing, microbiology, custom flow cytometry, electronic transmission of test results, biomarker development, adaptive trial design and execution, medical device trials, and healthcare communication services. ICON Public Limited Company was founded in 1990 and is headquartered in Dublin, Ireland.

11,300 Employees
Last Reported Date: 07/28/15
Founded in 1990

icon plc (ICLR) Top Compensated Officers

Chief Executive Officer, Director and Chairma...
Total Annual Compensation: $6.6M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: $1.8M
Chief Operating Officer
Total Annual Compensation: $3.0M
Compensation as of Fiscal Year 2014.

icon plc (ICLR) Key Developments

Icon Launches New Firecrest Patient Portal

ICON plc has launched the Firecrest Patient Portal. This portal enables patients to view clinical trial information and is specifically designed to enhance the patients understanding of treatment before consenting to participate at an investigator site. The Patient Portal solution is a component of ICON's new informatics hub designed to enhance the engagement of patient populations in the development process and is in line with ICH E6 guidance, which recommends patients receive 'ample time' to review consent materials and ask follow-up questions.

ICON Public Limited Company Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-10-2015 01:20 PM

ICON Public Limited Company Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-10-2015 01:20 PM. Venue: Four Seasons Hotel, Chicago, Illinois, United States. Speakers: Brendan Brennan, Chief Financial Officer and Member of Executive Committee.

Inform Genomics Selects ICON plc as Contract Research Organization (CRO) for Pivotal Multicenter Study of HSCT/Mucositis Product Candidate

Inform Genomics Inc. announced the selection of ICON plc as its contract research organization (CRO) for the pivotal multicenter study of its Hematopoietic Stem Cell Transplant (HSCT)/Mucositis™ product candidate. In the first phase of development, the HSCT/Mucositis™ product candidate demonstrated that it could accurately predict a patient's risk for developing oral mucositis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICLR:US $81.22 USD +0.42

ICLR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ergomed PLC 180.00 GBp 0.00
INC Research Holdings Inc $49.73 USD -0.30
PAREXEL International Corp $68.84 USD -0.12
PRA Health Sciences Inc $42.05 USD +0.06
WuXi PharmaTech Cayman Inc $41.70 USD +0.20
View Industry Companies

Industry Analysis


Industry Average

Valuation ICLR Industry Range
Price/Earnings 6.5x
Price/Sales 0.9x
Price/Book 1.3x
Price/Cash Flow 5.0x
TEV/Sales 0.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICON PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at